Locoregional Recurrence After Neoadjuvant Versus Adjuvant Chemotherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

10328 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-04-22

Study Completion Date

2023-09-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Neoadjuvant chemotherapy (NACT) for early-stage breast cancer is associated with an increased risk of locoregional recurrence (LRR). However, few studies have conducted subgroup analyses of patients with various molecular subtypes, which are one of the determinant factors for treatments. The aim of the study is to investigate whether the risk of LRR after NACT varies across tumor subtypes. The investigators retrospectively reviewed the medical records of female breast cancer patients who underwent breast-conserving surgery at three institutions between January 1, 2004, and Dec 31, 2018.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Patterns of Relapse After Neoadjuvant Chemotherapy in Breast Cancer

NCT06210347

Breast Cancer

NOT_YET_RECRUITING

Probability of OncotypeDx to Reallocate As Low or High Risk of Recurrence Breast Cancer Patients with Uncertain Biology

NCT06363812

Breast Cancer

COMPLETED

Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemotherapy

NCT04278469

Early Hormone Receptor-positive Breast Cancer

RECRUITING NA

Assessment of Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in ER-positive, Her2-negative Early Breast Cancer

NCT03080428

ER-positive Her2-negative Early Breast Cancer

WITHDRAWN NA

Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data (MONARCHE29)

NCT06621459

Brest Cancer Abemaciclib Adjuvant Therapy +2 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Neoadjuvant chemotherapy (NACT) group

Patients who administered chemotherapy before surgery

Neoadjuvant chemotherapy

Intervention Type PROCEDURE

Patients received neoadjuvant chemotherapy (either taxane-or anthracycline-based, or any cytotoxic chemotherapy) , followed by surgery and radiotherapy

Adjuvant chemotherapy (ACT) group

Patients who administered chemotherapy after surgery

Adjuvant chemotherapy

Intervention Type PROCEDURE

Patients received adjuvant chemotherapy (either taxane-or anthracycline-based, or any cytotoxic chemotherapy) after surgery, followed by radiotherapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neoadjuvant chemotherapy

Patients received neoadjuvant chemotherapy (either taxane-or anthracycline-based, or any cytotoxic chemotherapy) , followed by surgery and radiotherapy

Intervention Type PROCEDURE

Adjuvant chemotherapy

Patients received adjuvant chemotherapy (either taxane-or anthracycline-based, or any cytotoxic chemotherapy) after surgery, followed by radiotherapy

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NACT ACT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who underwent breast-conserving surgery for invasive breast cancer between 2004 and 2018

Exclusion Criteria

* Total mastectomy
* No pre- or postoperative chemotherapy
* No radiation therapy
* Bilateral breast cancer
* Male breast cancer patients
* Secondary breast cancer
* Metachronous or synchronous cancers

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No